|
Vygen-Bonnet S, Koch J, Bogdan C, et al.
(2022)
C1
Tags: 
Impfungen,
COVID-19,
Strategie,
Verteilung,
Ethik,
Risikogruppen,
Priorisierung,
Deutschland,
mRNA,
vector-basierter Impfstoff,
Astra Zeneca,
Moderna,
pfizer,
Risiko,
Sinusvenenthrombosen,
Zweitimpfung,
johnson&Johnson,
pediatrics,
Children,
Adolescents,
booster,
|
|
|
World Health Organization WHO
(2022)
C_WHO
|
|
|
Medicines and Healthcare products Regulatory Agency (MHRA) UK
(2021)
CC
REG 174 INFORMATION FOR UK HEALTHCARE PROFESSIONALS
|
|
|
World Health Organization WHO
(2021)
C_WHO
|
|
|
World Health Organization WHO
(2021)
C_WHO
|
|
|
European Medicines Agency EMA
(2021)
CC
|
|
|
Greinacher, A., et al.
(2021)
CC
New England Journal of Medicine
April 9, 2021
DOI: 10.1056/NEJMoa2104840
|
|
|
World Health Organization WHO
(2021)
C_WHO
|
|
|
Gesellschaft für Thrombose-undHämostaseforschung e.V. GTH
(2021)
CC
|
|
|
World Health Organization WHO, Regional Office of Europe
(2021)
C_WHO
|
|